{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:31:34Z","timestamp":1785843094274,"version":"3.56.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.autrev.2026.104035","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:14:56Z","timestamp":1773504896000},"page":"104035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting autoimmunity: Phosphodiesterase inhibitors as immunomodulators\u2014a review of current insights and future direction"],"prefix":"10.1016","volume":"25","author":[{"given":"Anna","family":"Bazs\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Szodoray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emese","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.autrev.2026.104035_bb0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2026.104035_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pharmtox-031524-025239","article-title":"Phosphodiesterase signaling and evolving implications for human therapeutics","volume":"65","author":"Kelly","year":"2025","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104035_bb0015","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","article-title":"Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents","volume":"109","author":"Lugnier","year":"2006","journal-title":"Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.autrev.2026.104035_bb0020","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrm911","article-title":"Cyclic nucleotide research\u2013still expanding after half a century","volume":"3","author":"Beavo","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.autrev.2026.104035_bb0025","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4541958","article-title":"Sildenafil can affect innate and adaptive immune responses in humans and animals","volume":"2017","author":"Kniotek","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2026.104035_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105134","article-title":"The immunomodulatory role of phosphodiesterase inhibitors in immune cells","volume":"161","author":"He","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.autrev.2026.104035_bb0035","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","article-title":"Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling","volume":"76","author":"Conti","year":"2007","journal-title":"Annu Rev Biochem"},{"issue":"7","key":"10.1016\/j.autrev.2026.104035_bb0040","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/01.RES.0000261934.56938.38","article-title":"cAMP-specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling","volume":"100","author":"Houslay","year":"2007","journal-title":"Circ Res"},{"issue":"11","key":"10.1016\/j.autrev.2026.104035_bb0045","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCRESAHA.106.144501","article-title":"cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology","volume":"100","author":"Zaccolo","year":"2007","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.autrev.2026.104035_bb0050","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.autrev.2026.104035_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100042","article-title":"Cyclic nucleotide phosphodiesterases as drug targets","volume":"77","author":"Kelly","year":"2025","journal-title":"Pharmacol Rev"},{"issue":"39","key":"10.1016\/j.autrev.2026.104035_bb0060","first-page":"re1","article-title":"Cyclic AMP: master regulator of innate immune cell function","volume":"1","author":"Serezani","year":"2008","journal-title":"Sci Signal"},{"key":"10.1016\/j.autrev.2026.104035_bb0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fimmu.2016.00123","article-title":"The cAMP pathway as therapeutic target in autoimmune and inflammatory diseases","volume":"7","author":"Raker","year":"2016","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104035_bb0070","first-page":"235","article-title":"Targeting phosphodiesterase-4 in respiratory disease: clinical perspectives","volume":"21","author":"Barnes","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2026.104035_bb0075","first-page":"78","article-title":"Life after PDE4: overcoming adverse events with dual- and multi-target drugs","volume":"32","author":"Giembycz","year":"2017","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104035_bb0080","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1124\/pr.110.002907","article-title":"cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide signaling and vascular function","volume":"62","author":"Francis","year":"2010","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.autrev.2026.104035_bb0085","article-title":"The role of nitric oxide-cGMP pathway in pulmonary arterial hypertension","volume":"57","author":"Ghofrani","year":"2021","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.autrev.2026.104035_bb0090","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pupt.2010.03.011","article-title":"The preclinical pharmacology of roflumilast \u2013 a selective, orally active PDE4 inhibitor","volume":"23","author":"Hatzelmann","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.autrev.2026.104035_bb0095","first-page":"47","article-title":"Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction","volume":"8","author":"Boolell","year":"1996","journal-title":"Int J Impot Res"},{"issue":"10","key":"10.1016\/j.autrev.2026.104035_bb0100","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","article-title":"Therapeutic targeting of 3\u2032,5\u2032-cyclic nucleotide phosphodiesterases: inhibition and beyond","volume":"18","author":"Baillie","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2026.104035_bb0105","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0771-6","article-title":"Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, modulates cytokine production through cAMP\/PKA\/Epac pathways","volume":"17","author":"Perez-Aso","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.autrev.2026.104035_bb0110","first-page":"759","article-title":"Phosphodiesterase isoforms and cAMP signalling revisited: new twists and therapeutic opportunities","volume":"21","author":"Kelly","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.autrev.2026.104035_bb0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1476-5381.2011.01218.x","article-title":"Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of COPD","volume":"163","author":"Rabe","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104035_bb0120","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S2213-2600(20)30225-3","article-title":"Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104035_bb0125","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.coph.2011.09.015","article-title":"From PDE3B to the regulation of energy homeostasis","volume":"11","author":"Degerman","year":"2011","journal-title":"Curr Opin Pharmacol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104035_bb0130","first-page":"621","article-title":"Compartmentalized cAMP signalling in immune cells","volume":"21","author":"Arp","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104035_bb0135","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.4049\/jimmunol.1001829","article-title":"The role of the transcription factor CREB in immune function","volume":"185","author":"Wen","year":"2010","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104035_bb0140","first-page":"1395","article-title":"cAMP: a multifaceted modulator of T-cell activation and differentiation","volume":"102","author":"Arumugham","year":"2017","journal-title":"J Leukoc Biol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104035_bb0145","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1165\/rcmb.2008-0091TR","article-title":"Cyclic AMP: master regulator of innate immune cell function","volume":"39","author":"Serezani","year":"2008","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104035_bb0150","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd2038","article-title":"NO-cGMP signaling in cardiovascular disease","volume":"5","author":"Evgenov","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"19","key":"10.1016\/j.autrev.2026.104035_bb0155","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","article-title":"Sildenafil in the treatment of Raynaud\u2019s phenomenon resistant to vasodilatory therapy","volume":"112","author":"Fries","year":"2005","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.autrev.2026.104035_bb0160","first-page":"933","article-title":"Phosphodiesterase-4 as a therapeutic target","volume":"4","author":"Houslay","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.autrev.2026.104035_bb0165","first-page":"443","article-title":"Role of cAMP phosphodiesterase 4 in T-cell activation","volume":"26","author":"Bjorgo","year":"2006","journal-title":"Crit Rev Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104035_bb0170","first-page":"4787","article-title":"PGE\u2082 induces macrophage IL-10 production and a regulatory-like phenotype via a cAMP\/PKA-CREB-CRTC3 pathway","volume":"190","author":"MacKenzie","year":"2013","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104035_bb0175","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","article-title":"New insights into the immunopathogenesis of systemic lupus erythematosus","volume":"12","author":"Tsokos","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104035_bb0180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0889-857X(03)00019-X","article-title":"Vascular disease in systemic sclerosis","volume":"29","author":"Hummers","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"issue":"10","key":"10.1016\/j.autrev.2026.104035_bb0185","first-page":"4783","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"192","author":"Schafer","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104035_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1407871","article-title":"PDE4 inhibitors: potential protective effects in inflammation, fibrosis and vascular disease","volume":"15","author":"Fan","year":"2024","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104035_bb0195","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/rheumatology\/keh552","article-title":"Pathogenesis of Raynaud\u2019s phenomenon","volume":"44","author":"Herrick","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2026.104035_bb0200","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nrrheum.2014.195","article-title":"A vascular mechanistic approach to understanding Raynaud phenomenon","volume":"11","author":"Flavahan","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104035_bb0205","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.01.020","article-title":"International consensus criteria for the diagnosis of Raynaud\u2019s phenomenon","volume":"48-49","author":"Maverakis","year":"2014","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.autrev.2026.104035_bb0210","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.berh.2016.04.001","article-title":"Raynaud\u2019s phenomenon","volume":"30","author":"Hughes","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"Suppl 106(4)","key":"10.1016\/j.autrev.2026.104035_bb0215","first-page":"42","article-title":"SPRING registry investigators. Prevalence and clinical relevance of digital ulcers in systemic sclerosis patients from real life: the experience of the SPRING registry of the Italian Society for Rheumatology","volume":"35","author":"Matucci-Cerinic","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104035_bb0220","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMra1507638","article-title":"Raynaud\u2019s phenomenon","volume":"375","author":"Wigley","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.autrev.2026.104035_bb0225","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJM200009213431207","article-title":"Thromboangiitis obliterans (Buerger\u2019s disease)","volume":"343","author":"Olin","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104035_bb0230","article-title":"Endothelial activation in thromboangiitis obliterans: mechanisms and therapeutic horizons","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104035_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2018.01840","article-title":"Mechanisms of endothelial dysfunction in antiphospholipid syndrome: association with clinical manifestations","volume":"9","author":"Vel\u00e1squez","year":"2018","journal-title":"Front Physiol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104035_bb0240","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.coph.2011.09.015","article-title":"From PDE3B to the regulation of energy homeostasis","volume":"11","author":"Degerman","year":"2011","journal-title":"Curr Opin Pharmacol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104035_bb0245","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nri2156","article-title":"Getting to the site of inflammation: the leukocyte adhesion cascade updated","volume":"7","author":"Ley","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104035_bb0250","first-page":"4783","article-title":"Apremilast, a cAMP phosphodiesterase 4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a murine model of psoriasis","volume":"192","author":"Schafer","year":"2014","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104035_bb0255","first-page":"494","article-title":"Crisaborole ointment for atopic dermatitis: PDE4 inhibition and clinical efficacy","volume":"75","author":"Eichenfield","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"9997","key":"10.1016\/j.autrev.2026.104035_bb0260","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.autrev.2026.104035_bb0265","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis","volume":"2","author":"Armstrong","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.autrev.2026.104035_bb0270","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: pooled safety analysis","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104035_bb0275","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"Update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2026.104035_bb0280","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0092-8674(01)00456-1","article-title":"Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity","volume":"106","author":"Liu","year":"2001","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.autrev.2026.104035_bb0285","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: mechanism of action, role in immune responses and disease","volume":"21","author":"Guo","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104035_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01067","article-title":"Beh\u00e7et\u2019s disease: an overview of etiopathogenesis","volume":"10","author":"Leccese","year":"2019","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104035_bb0295","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2013.161","article-title":"Immune mechanisms in giant cell arteritis","volume":"9","author":"Weyand","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104035_bb0300","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1742-1241.2002.tb11296.x","article-title":"Pharmacology of phosphodiesterase-5 inhibitors","volume":"56","author":"Corbin","year":"2002","journal-title":"Int J Clin Pract"},{"issue":"38","key":"10.1016\/j.autrev.2026.104035_bb0305","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"19","key":"10.1016\/j.autrev.2026.104035_bb0310","first-page":"1779","article-title":"Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis","volume":"387","author":"Richeldi","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104035_bb0315","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2026.104035_bb0320","article-title":"Portal hypertension and gastrointestinal bleeding","volume":"7","author":"Bosch","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.autrev.2026.104035_bb0325","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cld.2013.12.001","article-title":"Pathophysiology of portal hypertension","volume":"18","author":"Iwakiri","year":"2014","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104035_bb0330","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-12381-0","article-title":"Molecular patterns of the NO-sGC-cGMP pathway in progressive and regressive liver fibrosis models","volume":"15","author":"Sorz-Nechay","year":"2025","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.autrev.2026.104035_bb0335","first-page":"719","article-title":"Cyclic GMP in liver cirrhosis\u2013role in pathophysiology of portal hypertension and therapeutic implications","volume":"22","author":"Schwabl","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.autrev.2026.104035_bb0340","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11926-024-01155-8","article-title":"Rheumatoid arthritis-associated interstitial lung disease (RA-ILD): update on prevalence, risk factors, pathogenesis, and therapy","volume":"26","author":"Sullivan","year":"2024","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"10.1016\/j.autrev.2026.104035_bb0345","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1183\/13993003.00357-2015","article-title":"Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease","volume":"47","author":"Solomon","year":"2016","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.autrev.2026.104035_bb0350","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF): 2022 ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"10.1016\/j.autrev.2026.104035_bb0355","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2026.104035_bb0360","first-page":"789","article-title":"Nerandomilast in patients with idiopathic pulmonary fibrosis","volume":"390","author":"Richeldi","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.autrev.2026.104035_bb0365","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104035_bb0370","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.778649","article-title":"Autoimmune progressive fibrosing interstitial lung disease: predictors of fast decline","volume":"12","author":"Nagy","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104035_bb0375","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01899-2018","article-title":"Genetics and genomics of pulmonary arterial hypertension","volume":"53","author":"Morrell","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.autrev.2026.104035_bb0380","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.autrev.2026.104035_bb0385","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01325-2024","article-title":"Treatment algorithm for pulmonary arterial hypertension","volume":"64","author":"Chin","year":"2024","journal-title":"Eur Respir J"},{"issue":"21","key":"10.1016\/j.autrev.2026.104035_bb0390","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.autrev.2026.104035_bb0395","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","article-title":"Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104035_bb0400","article-title":"Anti-inflammatory and antifibrotic potential of PDE4B inhibition in progressive pulmonary fibrosis","volume":"63","author":"Maher","year":"2024","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.autrev.2026.104035_bb0405","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.autrev.2026.104035_bb0410","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/MCP.0000000000000712","article-title":"Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies","volume":"26","author":"Wongkarnjana","year":"2020","journal-title":"Curr Opin Pulm Med"},{"issue":"18","key":"10.1016\/j.autrev.2026.104035_bb0415","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases: results of the INBUILD trial","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.autrev.2026.104035_bb0420","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"issue":"12 Suppl S","key":"10.1016\/j.autrev.2026.104035_bb0425","doi-asserted-by":"crossref","first-page":"68S","DOI":"10.1016\/j.jacc.2004.02.031","article-title":"Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension","volume":"43","author":"Ghofrani","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104035_bb0430","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMoa1803583","article-title":"Phase II trial of ibudilast in progressive multiple sclerosis: SPRINT-MS","volume":"379","author":"Fox","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:31:34Z","timestamp":1775053894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226000492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1568997226000492"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104035","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting autoimmunity: Phosphodiesterase inhibitors as immunomodulators\u2014a review of current insights and future direction","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104035"}}